We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

161 hedge funds and large institutions have $623M invested in Coherus Oncology in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 60 increasing their positions, 55 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.54% more ownership

Funds ownership: 99.55% → 101.09% (+1.5%)

9% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 55

6% less call options, than puts

Call options by funds: $1.18M | Put options by funds: $1.26M

7% less funds holding

Funds holding: 174 → 161 (-13)

16% less capital invested

Capital invested by funds: $744M → $623M (-$121M)

39% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 31

Holders
161
Holders Change
-13
Holders Change %
-7.47%
% of All Funds
2.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
60
Reduced
55
Closed
31
Calls
$1.18M
Puts
$1.26M
Net Calls
-$81K
Net Calls Change
+$594K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$12.9M
2
Citadel Advisors
Citadel Advisors
Florida
+$8.65M
3
BlackRock
BlackRock
New York
+$8.44M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$4.52M
5
JP Morgan Chase
JP Morgan Chase
New York
+$2.92M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$16M
2
TLP
Tri Locum Partners
New York
-$6.12M
3
TCM
Tang Capital Management
California
-$4.88M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.88M
5
Deutsche Bank
Deutsche Bank
Germany
-$2.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$4.01M +$111K +14,446 +3%
Rafferty Asset Management
27
Rafferty Asset Management
New York
$3.72M +$1.54M +200,546 +75%
N
28
Nuveen
North Carolina
$3.66M -$2.05M -266,911 -37%
CS
29
Credit Suisse
Switzerland
$3.47M -$270K -35,087 -7%
Macquarie Group
30
Macquarie Group
Australia
$3.41M -$4.55K -591 -0.1%
Principal Financial Group
31
Principal Financial Group
Iowa
$3.26M -$151K -19,686 -5%
Bank of America
32
Bank of America
North Carolina
$3.03M +$857K +111,370 +41%
Invesco
33
Invesco
Georgia
$2.71M +$202K +26,220 +8%
Deutsche Bank
34
Deutsche Bank
Germany
$2.61M -$2.68M -348,122 -51%
Lazard Asset Management
35
Lazard Asset Management
New York
$2.52M +$1.21M +156,746 +97%
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$2.51M +$43.4K +5,634 +2%
PAMS
37
Pictet Asset Management (Switzerland)
Switzerland
$2.46M +$601K +78,160 +34%
UBS Group
38
UBS Group
Switzerland
$2.42M +$2.01M +260,697 +580%
Barclays
39
Barclays
United Kingdom
$2.37M +$725K +94,202 +46%
Balyasny Asset Management
40
Balyasny Asset Management
Illinois
$2.34M -$3.88M -504,073 -63%
Two Sigma Advisers
41
Two Sigma Advisers
New York
$1.72M +$309K +40,200 +23%
CSS
42
Cubist Systematic Strategies
Connecticut
$1.61M -$165K -21,404 -10%
KCM
43
Kennedy Capital Management
Missouri
$1.6M -$231 -30 -0%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$1.55M +$65.5K +8,508 +5%
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$1.5M +$430K +55,906 +42%
AA
46
AlphaCentric Advisors
Puerto Rico
$1.49M +$1.03M +134,500 +254%
CM
47
CM Management
Florida
$1.39M -$192K -25,000 -13%
BCC
48
Bridge City Capital
Oregon
$1.32M -$8.81K -1,145 -0.7%
Legal & General Group
49
Legal & General Group
United Kingdom
$1.25M +$22.9K +2,979 +2%
Swiss National Bank
50
Swiss National Bank
Switzerland
$1.19M +$25.4K +3,300 +2%
1
2
3 4 5

CHRS Hedge Fund Activity: Q4 2022 in Review

161 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2022, worth a combined $623M — down 16% from $744M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of CHRS and 19 opened new positions — a net loss of 12 holders — while 55 trimmed existing stakes and 60 added.

The largest buyer was State Street, adding an estimated $12.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $16M sold.

  • 161 institutional investors held Coherus Oncology (CHRS) as of Q4 2022, down from 174 in Q3 2022.
  • Funds reported $623M of Coherus Oncology stock for Q4 2022, down 16% quarter-over-quarter.
  • 19 funds opened new Coherus Oncology positions in Q4 2022 and 31 closed out, a net change of -12 holders.
  • The largest Coherus Oncology buyer in Q4 2022 was State Street, an estimated $12.9M added.
  • The largest Coherus Oncology seller in Q4 2022 was Perceptive Advisors, an estimated $16M sold.

Based on aggregated 13F filings for Q4 2022.